OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Outlook Therapeutics, Inc.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026
$0.49+0.00 (+0.98%)
Close on Oct 19, 2026
- Market cap
- $67.41M
- P/E (TTM)
- –
- Dividend yield
- –
Outlook Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Outlook Therapeutics | Industry median |
|---|---|---|
| Market Cap | $120.02M | $164.85M |
| Enterprise Value | $108.78M | $87.06M |
Income (trailing twelve months)
| Measure | Outlook Therapeutics | Industry median |
|---|---|---|
| Gross Profit | -$2.28M | $90.47M |
| Operating Income | -$55.64M | -$21.44M |
| Net Income | -$61.12M | -$22.46M |
| EBITDA | -$55.53M | -$16.91M |
| EPS (Diluted) | -$0.86 | -$0.83 |
Returns
| Measure | Outlook Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -251.7% | -41.0% |
Balance sheet
| Measure | Outlook Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $11.24M | $62.42M |
| Net Cash (Debt) | $11.24M | $15.68M |
| Net Cash Per Share | $0.05 | $0.66 |
| Equity (Book Value) | -$10.39M | $48.79M |
| Book Value Per Share | -$0.04 | $1.36 |
| Tangible Book Value | -$10.39M | $23.06M |
| Working Capital | -$5.51M | $75.77M |
Financial position
| Measure | Outlook Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.81 | 3.30 |
| Quick Ratio | 0.45 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Outlook Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$56.15M | -$12.35M |
Efficiency
| Measure | Outlook Therapeutics | Industry median |
|---|---|---|
| Inventory Turnover | 0.24 | 2.67 |
| Profits Per Employee | -$3.60M | -$703.34K |
| Employee Count | 17 | 74 |
Dividends and yields
| Measure | Outlook Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -50.9% | -22.7% |
| Buyback Yield | -45.5% | -0.73% |
| Shareholder Yield | -45.5% | 0.00% |
Shares
| Measure | Outlook Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 243,448,000 | 58,179,650 |
| Shares Change (YoY) | 181.5% | 11.1% |
| Shares Change (QoQ) | 78.8% | 0.54% |
| Float | 174,157,000 | 49,173,100 |
| Shares Held by Insiders | 28.5% | 11.6% |
| Shares Held by Institutions | 8.40% | 59.4% |
Scores
| Measure | Outlook Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -40.24 | -0.24 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Outlook Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.